Over the past four decades, antibody discovery platforms have transformed biotherapeutics. Hybridoma technology, developed in 1975, pioneered the production of monoclonal antibodies, while more recent advances in single B cell screening have expanded access to rare, high-affinity clones.
DOI: 10.3389/fimmu.2021.7532941. Structural Overview of AntibodiesAntibodies, or immunoglobulins (Igs), are glycoproteins produced by plasma cells as part of the adaptive immune response. They are composed of two identical heavy chains (~50 kDa each) and two identical light chains (~25 kDa each), co
Cambridge Healthtech Institute’s 13th Annual 2025 Immuno-Oncology Summit was held in Philadelphia, PA, USA, from August 11-13. Read on for a summary of the event spanning solid tumor innovations and antibody therapeutics.
抗体薬物複合体（Antibody-Drug Conjugates, ADC）は、がん治療において革新的なターゲット型治療薬の一つであり、モノクローナル抗体（mAb）の高い特異性と、低分子抗がん薬の強力な細胞障害作用を組み合わせたものです。この構造により、ADCは化学療法薬をがん細胞に選択的に送達し、正常組織へのダメージを最小限に抑えることを目的としています。
ADLM 2025 was held in Chicago, IL, USA, from July 27-31. The Association for Diagnostics & Laboratory Medicine event hosted global leaders in clinical chemistry, molecular diagnostics, mass spectrometry, translational medicine, lab management, and other areas of breaking science in laboratory me
CHOK1BN: A proven CHO cell line with high productivity, stability, and global compliance. License from Biointron for antibody manufacturing success.
Afucosylated antibodies boost ADCC by enhancing FcγRIIIa binding on NK cells. Biointron highlights their engineering, clinical approvals, and growing therapeutic applications.
Recombinant proteins fuel research and therapy. Biointron explains their design, production, and importance in biotechnology.
Top companies are driving ADC innovation in 2025. Biointron highlights key players advancing antibody-drug conjugate pipelines.
V(D)J recombination generates antibody diversity. Biointron explains its molecular basis and importance in adaptive immunity.
ScientistとScience Exchangeとのご利用可能です。